Prevention & lipids

Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

N Engl J MedPublished international, randomized, placebo-controlled trial

Primary result · Major adverse cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization)Result — go to the resultHazard ratio 1.02 95% CI 0.90–1.15

Authors' conclusion

Pelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years. (Funded by Novartis; Lp[a]HORIZON ClinicalTrials.gov number, NCT04023552.)See also in NEJM Evidence: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).

Study context

Population
Patients with preexisting cardiovascular disease and a lipoprotein(a) level of at least 70 mg per deciliterunderwent randomization, 8322 included in the efficacy analysis
Participants
8,350 patients
Comparison
Pelacarsen vs placebo
  • Pelacarsenn = 4,157
  • Placebon = 4,165reference
Primary endpoint
Major adverse cardiovascular event:
  • Death from cardiovascular causes
  • Nonfatal myocardial infarction
  • Nonfatal stroke
  • Urgent coronary revascularization
Follow-up
Median 4.7 years

Primary result

Major adverse cardiovascular event…

Hazard ratio

1.02

95% CI 0.90–1.15

P = 0.76

Events by treatment group

Pelacarsenvs Placebo
hazard ratio 1.02 (95% CI 0.90–1.15); P = 0.76

As reported in the abstract

Further findings

Lipoprotein(a) level · 12 months

OutcomePelacarsenPlaceboHazard ratio (95% CI)P value
Primary end point among patients with baseline lipoprotein(a) of at least 90 mg per deciliter (subgroup)12.3%12.3%1.00 (0.87–1.15)P = 0.99
  • Lipoprotein(a) level: median baseline 236 nmol per liter

Safety

Serious adverse events

Original publication

Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). N Engl J Med. Published 7 November 2026. doi:10.1056/nejmoa2610159

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.